BIOTECH firm Tissue Regenix has set up a subsidiary company in the United States to target the growing regenerative medicine market.
The York-based business said the move comes as part of its commercialisation strategy for its dCELL technology platform.
Its patented decellularisation or dCELL process removes cells from human and animal tissue, leaving a scaffold which can be inserted into the body and repopulated with new cells. Products being developed using the dCELL process include vascular patches to repair damaged blood vessels, replacement knee tissue and parts for heart surgery.
Tissue Regenix has also announced the appointment of Greg Bila from Kinetic Concepts Inc. as president of Tissue Regenix USA. His recent career at KCI has spanned a number of sales and marketing roles and brings over 20 years’ experience in pharmaceutical and medical device fields.
Antony Odell, managing director of Tissue Regenix, said: “This is a significant step in the development of Tissue Regenix. It is an excellent signal of the strength of TR’s proposition that we can attract people of Greg’s calibre and experience, we look forward to advancing our plans in the US with him at the helm. The United States presents an opportunity to establish our platform dCELL technology in a market potentially worth hundreds of millions of dollars.”
Greg Bila, president of Tissue Regenix Wound Care Inc. said: “I am excited to be able to join Tissue Regenix at the beginning of its expansion into the United States. TR’s dCELL technology will be a welcome offering for the treatment of number of diseases and the potential indications are attractive.”